Are big muscles necessarily good muscles?

Annals of Neurology

Volumn 63, Issue 5, 2008, Pages 543-545

  Nadeau, Amelie ^a   Karpati, George ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER GROWTH FACTOR; DYSTROPHIN; GROWTH FACTOR; MYO 029; MYOSTATIN; PLACEBO; PROTEIN GDF8; RECOMBINANT ANTIBODY; RECOMBINANT MYOSTATIN ANTIBODY; UNCLASSIFIED DRUG; ANTIBODY; STAMULUMAB; TRANSFORMING GROWTH FACTOR BETA;

CLINICAL TRIAL; DRUG SAFETY; EDITORIAL; GENE MUTATION; HUMAN; MUSCLE ATROPHY; MUSCLE HYPERTROPHY; MUSCLE WEAKNESS; MUSCULAR DYSTROPHY; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BIOLOGICAL MODEL; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; NOTE; ORGAN SIZE; PATHOPHYSIOLOGY; SKELETAL MUSCLE;

ANIMALS; ANTIBODIES; CLINICAL TRIALS AS TOPIC; HUMANS; MODELS, BIOLOGICAL; MUSCLE, SKELETAL; MUSCULAR DYSTROPHIES; ORGAN SIZE; TRANSFORMING GROWTH FACTOR BETA;

EID: 44849119138     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.21395     Document Type: Editorial

References (17)

1. Carpenter S, Karpati G. Pathology of skeletal muscle. 2nd ed. New York: Oxford University Press, 2001.
2. Patel K, Muntoni F. Inducing muscle hypertrophy as a therapeutic strategy for muscular dystrophies. 122nd ENMC International Workshop, Naarden, The Netherlands, 28-30 November 2003. Neuromuscul Disord 2004;14:519-525.
3. Patel K, Amthor H. The function of myostatin and strategies of myostatin blockade - new hope for therapies aimed at promoting growth of skeletal muscle. Neuromuscul Disord 2005;15:117-126.
4. McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 1997;387:83-90.
5. Joulia-Ekaza D, Cabello G. Myostatin regulation of muscle development: molecular basis, natural mutations, physiopathological aspects. Exp Cell Res 2006;312:2401-2414.
6. Amthor H, Huang R, McKinnell I, et al. The regulation and action of myostatin as a negative regulator of muscle development during avian embryogenesis. Dev Biol 2002;251:241-257.
7. McFarlane C, Plummer E, Thomas M, et al. Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-kappaB-independent, FoxO1-dependent mechanism. J Cell Physiol 2006;209:501-514.
8. Grobet L, Martin LJ, Poncelet D, et al. A deletion in the bovine myostatin gene causes the double-muscled phenotype in cattle. Nat Genet 1997;17:71-74.
9. Wagner KR, McPherron AC, Winik N, Lee SJ. Loss of myostatin attenuates severity of muscular dystrophy in mdx mice. Ann Neurol 2002;52:832-836.
10. Bogdanovich S, Krag TO, Barton ER, et al. Functional improvement of dystrophic muscle by myostatin blockade. Nature 2002;420:418-421.
11. Li ZF, Shelton GD, Engvall E. Elimination of myostatin does not combat muscular dystrophy in dy mice but increases postnatal lethality. Am J Pathol 2005;166:491-497.
12. Parsons SA, Millay DP, Sargent MA, et al. Age-dependent effect of myostatin blockade on disease severity in a murine model of limb-girdle muscular dystrophy. Am J Pathol 2006;168:1975-1985.
13. Wagner KR, Fleckenstein JL, Amato AA, et al. A phase I/II trial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol 2008;63:561-571.
14. Kishnani PS, Corzo D, Nicolino M, et al. Recombinant human acid α-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 2007;68:99-109.
15. Lee SJ, McPherron AC. Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci U S A 2001;98:9306-9311.
16. Karpati G, Carpenter S. Small-caliber skeletal muscle fibers do not suffer deleterious consequences of dystrophic gene expression. Am J Med Genet 1986;25:653-658.
17. Muntoni F, Wells D. Genetic treatments in muscular dystrophies. Curr Opin Neurol 2007;20:590-594.